Application of DFO and composition thereof in functional recovery after ovarian transplantation

By employing a combined drug delivery strategy of DFO and VEGF-A, the problems of follicle loss and insufficient functional recovery after ovarian transplantation were addressed, resulting in an increase in the number of follicles and the restoration of ovarian function and structure. This approach provides safe and effective drugs and drug combination regimens.

CN121943897APending Publication Date: 2026-05-01NAT HEALTH COMMISSION INST OF SCI & TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610166556.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2025-09-25
Filing Date
2026-02-05
Publication Date
2026-05-01

AI Technical Summary

Technical Problem

Ovarian transplantation results in severe follicle loss and a shortened recovery period for ovarian function. Current technologies are insufficient to effectively improve follicle survival rates and promote ovarian function recovery.

Method used

By employing a combined administration strategy of DFO and its pharmaceutically acceptable salts with VEGF-A or its pharmaceutically acceptable salts, through local or systemic administration, synergistic effects can be achieved to promote functional recovery after ovarian transplantation.

Benefits of technology

It significantly improves follicle survival rate, increases follicle number, restores ovarian function and structure, and provides safe and effective drug and drug combination strategies to promote functional recovery after ovarian transplantation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121943897A_ABST
    Figure CN121943897A_ABST
Patent Text Reader

Abstract

The invention discloses application of DFO and a composition thereof in functional recovery after ovarian transplantation. It is found for the first time that deferoxamine (DFO) can effectively improve the survival rate of follicles, increase the number of follicles and recover the functional structure of an ovary. In addition, it is found for the first time that the combination of DFO and vascular endothelial growth factor A (VEGF-A) has a synergistic effect on functional recovery after ovarian transplantation. The invention provides an effective drug and a drug combination strategy for functional recovery after ovarian transplantation, and has a wide application prospect in the technical field of development of repair drugs after ovarian transplantation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomedical technology, specifically relating to the application of DFO and its compositions in the functional recovery after ovarian transplantation. Background Technology

[0002] With advancements in the diagnosis and treatment of malignant tumors, the survival rate of patients has significantly improved. However, female patients undergoing chemotherapy and radiotherapy often experience damage to their gonadal function, leading to decreased fertility. Clinicians and laboratory personnel can use surgery, medication, or laboratory techniques to help women at risk of infertility or men at risk of infertility to protect and preserve their ability to produce genetically inherited offspring—a process known as fertility preservation. For pre-pubertal women, women requiring immediate treatment for malignant tumors, and women with hormone-sensitive tumors (such as estrogen receptor-positive breast cancer), ovarian tissue cryopreservation is an effective option for fertility preservation.

[0003] Ovarian tissue cryopreservation-thaw transplantation involves surgically removing all or part of the ovaries of patients requiring fertility preservation, fragmenting them, freezing them, and then storing them in liquid nitrogen or a mechanical freezer for long-term cryopreservation. After the disease is cured, the cryopreserved ovarian tissue is thawed and transplanted back into the body. Although most cases where ovarian tissue is thawed and transplanted back into the pelvic cavity restore ovarian function, the duration of ovarian function after transplantation is significantly shortened, with most follicles lost during the cryopreservation-thaw transplantation process. How to reduce follicle loss during treatment, improve the follicle survival rate of transplanted ovarian tissue, and promote the recovery of ovarian function after transplantation have become urgent technical problems to be solved in the field of fertility preservation. Summary of the Invention

[0004] As used in this invention, the terms “having,” “comprising,” or “including,” or any grammatical variations thereof, are used in a non-exclusive manner. Thus, these terms can all refer to a situation where no other features exist in the entity described in this context besides the features introduced by these terms, and can also refer to a situation where one or more other features are present.

[0005] Furthermore, as used in this invention, the terms “preferred,” “more preferred,” “most preferred,” “particularly,” “more particularly,” “specifically,” “more specifically,” or similar terms are used in combination with optional features without limiting other possibilities.

[0006] Unless otherwise stated, all figures used in this specification and claims to represent volume, weight, temperature, time, density, parts by weight, technical effect, etc., should in any case be understood to be modified by the terms "about" or "approximately". Therefore, unless indicated to the contrary, the numerical parameters listed in the specification and appended claims are approximate values. Unless otherwise stated, the terminology used herein has its common meaning as understood by one of ordinary skill in the art, and each numerical parameter should be interpreted according to the number of significant figures and conventional rounding methods or in a manner understood by one of those skilled in the art.

[0007] To overcome the shortcomings of the prior art, the present invention provides the application of DFO and its compositions in ovarian function recovery after transplantation, and provides a safe and effective drug, pharmaceutical composition, pharmaceutical preparation, intelligent diagnostic and treatment method, system, device, computationally readable storage medium or computer program product, including computer program, for ovarian function recovery after transplantation.

[0008] To achieve the above objectives, the present invention adopts the following technical solution: The first aspect of the present invention provides a drug for promoting the functional recovery of ovarian transplantation, said drug being DFO or its pharmaceutically acceptable salt.

[0009] Furthermore, the DFO or its pharmaceutically acceptable salt contains 100 mg per kilogram.

[0010] In some embodiments, the pharmaceutically acceptable salt is safe and effective for topical application in mammals and possesses the desired biological activity. Pharmaceutically acceptable salts include salts of acidic or basic groups present in the specified compound. Pharmaceutically acceptable acid addition salts include, but are not limited to, hydrochlorides, hydrobromides, hydroiodates, nitrates, sulfates, hydrogen sulfates, phosphates, acid phosphates, isonicotinate, acetates, lactates, salicylates, citrates, tartrates, pantothenates, hydrogen tartrate, ascorbic acid salts, succinates, maleates, gentisinates, fumarates, glucurons, glucuronides, sucrose salts, formates, benzoates, glutamates, methanesulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, and papoate (i.e., L, L'). Methylene two (2 hydroxyl 3 Naphthyl carbamates). Certain compounds used in this invention can form pharmaceutically acceptable salts with various amino acids. Suitable alkaline salts include, but are not limited to, aluminum, calcium, lithium, magnesium, potassium, sodium, zinc, and diethanolamine salts.

[0011] In some embodiments, the hydrate, enantiomer, diastereomer, solvate, crystalline form or derivative thereof corresponding to DFO are also within the scope of protection of this invention. That is, the use of the hydrate, enantiomer, diastereomer, solvate, crystalline form or derivative thereof corresponding to DFO in the preparation of drugs that promote the functional recovery of ovarian transplantation also falls within the scope of protection of this invention.

[0012] A second aspect of the present invention provides a pharmaceutical composition for promoting functional recovery after ovarian transplantation, wherein the active ingredient of the pharmaceutical composition comprises DFO or a pharmaceutically acceptable salt thereof in combination with VEGF-A or a pharmaceutically acceptable salt thereof.

[0013] Furthermore, the mass ratio of DFO or its pharmaceutically acceptable salt to VEGF-A or its pharmaceutically acceptable salt is 100:0.008.

[0014] Furthermore, the individual mass of the DFO or its pharmaceutically acceptable salt is 100 mg per kilogram.

[0015] Furthermore, the individual mass of the VEGF-A or its pharmaceutically acceptable salt is 8 μg per kilogram.

[0016] Furthermore, the DFO or its pharmaceutically acceptable salt, combined with VEGF-A or its pharmaceutically acceptable salt, has a synergistic effect on the functional recovery of ovarian transplantation.

[0017] In some embodiments, DFO or a pharmaceutically acceptable salt thereof and VEGF-A or a pharmaceutically acceptable salt thereof in the pharmaceutical composition may be administered simultaneously, separately, or sequentially. Simultaneous administration means that the two drugs are administered concurrently. If not administered simultaneously, they are administered sequentially within a time frame so that both can be therapeutically effective within the same time frame. Therefore, sequential administration allows for the administration of one drug 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, or several hours after administering one drug, provided that the circulating half-life of the first administered drug allows for the simultaneous presence of therapeutically effective amounts of both. The time delay between administrations of the components will vary depending on the exact nature of the components, their interactions, and their respective half-lives. This differs from simultaneous or sequential administration, which refers to a significant interval between the administration of one drug and another, i.e., when the second drug is administered, the first administered drug may no longer be present in the bloodstream at a therapeutically effective amount.

[0018] In some embodiments, the pharmaceutical composition of the present invention may also be used in combination with other therapeutic compounds that can be used for the treatment and / or adjuvant treatment of ovarian transplantation functional recovery. These other therapeutic compounds may be administered simultaneously with the main active ingredient in the pharmaceutical composition of the present invention, or even simultaneously within the same composition. Other therapeutic compounds may also be administered alone as a single composition or in a dosage form different from that of the main active ingredient. A portion of the main ingredient may be administered simultaneously with other therapeutic compounds, while other doses may be administered alone. During treatment, the dosage of the pharmaceutical composition of the present invention may be adjusted according to the severity of symptoms, the frequency of relapse, and the physiological response to the treatment regimen.

[0019] In some implementations, a therapeutically effective amount refers to the amount of an active compound or pharmaceutical agent that elicits a biological or medical response sought by researchers, veterinarians, physicians, or other clinicians in a tissue, system, animal, or human. The therapeutically or pharmaceutically effective amount of the compound to be administered will be determined by such considerations and is the minimum amount necessary to improve, cure, or treat a disease or condition or one or more of its symptoms. The pharmaceutical composition of the invention will be formulated, administered, and applied in a manner consistent with good medical practice, i.e., the dosage, concentration, regimen, process, medium, and route of administration. Factors considered in this context include the specific condition being treated, the specific mammal being treated, the individual patient's clinical condition, the cause of the condition, the site of delivery, the method of administration, the administration regimen, and other factors known to a medical professional, such as the individual patient's age, weight, and response.

[0020] In some embodiments, the subject may be human or non-human and may include, for example, animal strains or species used as a “model system” for research purposes. Similarly, the subject may include adults or adolescents (e.g., children). Furthermore, the subject may refer to any living organism, preferably a mammal (e.g., human or non-human). Examples of mammals include, but are not limited to, any member of the mammalian class: humans, non-human primates (e.g., chimpanzees) and other apes and monkeys; livestock, such as cattle, horses, sheep, goats, pigs; domestic animals, such as rabbits, dogs, and cats; laboratory animals include rodents, such as rats, mice, and guinea pigs. Examples of non-mammals include, but are not limited to, birds, fish, etc.

[0021] The third aspect of the present invention provides the use of the DFO or its pharmaceutically acceptable salt described in the first aspect of the present invention, or the DFO or its pharmaceutically acceptable salt described in the second aspect of the present invention, in combination with VEGF-A or its pharmaceutically acceptable salt, in the preparation of a medicament for promoting the functional recovery of ovarian transplantation.

[0022] The fourth aspect of the present invention provides a pharmaceutical preparation for promoting the functional recovery of the ovary after transplantation, the pharmaceutical preparation comprising the drug described in the first aspect of the present invention or the pharmaceutical composition described in the second aspect of the present invention.

[0023] Furthermore, the pharmaceutical preparation also includes pharmaceutically acceptable excipients.

[0024] In some embodiments, the pharmaceutically acceptable excipients of the present invention include, but are not limited to: diluents, binders, surfactants, humectants, adsorbents, lubricants, fillers, and disintegrants.

[0025] In specific implementation schemes, the diluents include, but are not limited to: lactose, sodium chloride, glucose, urea, starch, water, etc.

[0026] In specific implementation schemes, the adhesive includes, but is not limited to: starch, pregelatinized starch, dextrin, maltodextrin, sucrose, gum arabic, gelatin, methylcellulose, carboxymethylcellulose, ethylcellulose, polyvinyl alcohol, polyethylene glycol, polyvinylpyrrolidone, alginate and alginate, xanthan gum, hydroxypropylcellulose, hydroxypropylmethylcellulose, etc.

[0027] In specific implementations, the surfactants include, but are not limited to: polyethylene oxide sorbitan fatty acid ester, sodium lauryl sulfate, glyceryl monostearate, hexadecyl alcohol, etc.

[0028] In specific implementation schemes, the humectant includes, but is not limited to, glycerin, starch, etc.

[0029] In specific implementation schemes, the adsorbent carriers include, but are not limited to, starch, lactose, bentonite, silica gel, kaolin, soap clay, etc.

[0030] In specific implementation schemes, the lubricant includes, but is not limited to: zinc stearate, glyceryl monostearate, polyethylene glycol, talc, calcium and magnesium stearate, polyethylene glycol, boric acid powder, hydrogenated vegetable oil, sodium stearate fumarate, polyoxyethylene monostearate, monolauric sucrose ester, sodium lauryl sulfate, magnesium lauryl sulfate, magnesium dodecyl sulfate, etc.

[0031] In specific implementation schemes, the fillers include, but are not limited to: mannitol, xylitol, sorbitol, maltose, erythrose, microcrystalline cellulose, polysaccharides, coupled sugars, glucose, lactose, sucrose, dextrin, starch, sodium alginate, kelp polysaccharide powder, agar powder, calcium carbonate, sodium bicarbonate, etc.

[0032] In specific implementation schemes, the disintegrants include, but are not limited to: crosylvinylpyrrolidone, sodium carboxymethyl starch, low-substituted hydroxypropyl methyl, crosylcarboxymethyl cellulose sodium, soybean polysaccharides, etc.

[0033] In some embodiments, the pharmaceutical composition of the present invention may further include additives such as stabilizers, buffers, bactericides, isotonic agents, pH control agents, surfactants, and chelating agents.

[0034] Furthermore, the dosage form of the pharmaceutical preparation includes oral dosage form, parenteral dosage form, or topical dosage form.

[0035] In some embodiments, the present invention does not particularly limit the dosage form of the pharmaceutical preparation, which can be any dosage form suitable for oral, parenteral, or topical administration, including but not limited to: injections, tablets, capsules, granules, powders, powders for injection, transdermal patches, ointments, gels, suppositories, oral solutions, oral suspensions, emulsions for injection, oral emulsions, sustained-release tablets, and controlled-release tablets. All of the above-mentioned dosage forms of pharmaceutical preparations can be prepared according to conventional methods in the pharmaceutical field.

[0036] The fifth aspect of this invention provides an intelligent diagnostic and treatment method for post-ovarian transplant function recovery based on DFO or its pharmaceutically acceptable salts combined with VEGF-A or its pharmaceutically acceptable salts, the method comprising the following steps: S101: Obtain relevant post-ovarian transplant functional information for the subject.

[0037] S102: Determine whether the subject is a patient whose ovarian function needs to be repaired after ovarian transplantation based on the relevant post-transplantation functional information data of the subject.

[0038] S103: When the subject is a patient whose ovarian function needs to be repaired after ovarian transplantation, the following treatment regimen shall be selected: administer a therapeutically effective amount of DFO or its pharmaceutically acceptable salt in combination with VEGF-A or its pharmaceutically acceptable salt to the subject.

[0039] Furthermore, the functional information following ovarian transplantation includes surgical history, symptoms and / or examination data: laboratory test data and / or pathological examination data.

[0040] Furthermore, if the laboratory test data shows that the subject's number of follicles, primordial follicle ratio, and / or antral follicle ratio are below the normal range, the atretic follicle ratio is above the normal range, and / or the pathological examination data shows ovarian tissue structure damage, then the subject will be matched as a patient whose ovarian function needs to be repaired after ovarian transplantation.

[0041] If the laboratory test data shows that the subject's follicle count, primordial follicle ratio, antral follicle ratio, and / or atretic follicle ratio are within the normal range and / or the pathological examination data shows that the ovarian tissue structure is intact, then the subject will be matched as a non-ovarian transplant recipient with functional repair needs.

[0042] The sixth aspect of this invention provides an intelligent diagnostic and treatment system for post-ovarian transplant functional recovery based on DFO or its pharmaceutically acceptable salts in combination with VEGF-A or its pharmaceutically acceptable salts, the system comprising: A diagnostic element information collector is used to collect functional element information after ovarian transplantation as described in the fifth aspect of the present invention and send the collected data results to a disease diagnosis matcher.

[0043] The disease diagnosis matcher is used to match the functional element information of the diagnostic element information collector with the disease type, and send the matched data results to the treatment plan matcher.

[0044] The treatment plan matcher is used to determine the matching result of the disease diagnosis matcher and call up the treatment plan according to the result, and then send the treatment plan data result to the disease diagnosis and treatment information output device.

[0045] The disease diagnosis and treatment information output device is used to output the data results received from the disease diagnosis matcher and treatment plan matcher to the receiving unit.

[0046] In the treatment plan matcher, if the disease diagnosis matcher matches the subject as a patient whose ovarian function needs to be repaired after ovarian transplantation, the following treatment plan is matched and invoked: administering a therapeutically effective amount of DFO or its pharmaceutically acceptable salt in combination with VEGF-A or its pharmaceutically acceptable salt to the subject.

[0047] In the treatment matching device, if the disease diagnosis matching device matches the subject as a non-ovarian transplant patient requiring functional repair, then there is no need to match and invoke the following treatment plan: administering a therapeutically effective amount of DFO or its pharmaceutically acceptable salt in combination with VEGF-A or its pharmaceutically acceptable salt to the subject.

[0048] Furthermore, the receiving unit can be a display screen, a computer client, a mobile client, or a tablet.

[0049] The seventh aspect of this invention provides a computer device, a computationally readable storage medium, or a computer program product for intelligent diagnosis and treatment of ovarian function recovery after transplantation based on DFO or its medicinal salts combined with VEGF-A or its medicinal salts. The device includes a computer program, and the device includes a memory and a processor. The memory stores program instructions, and the processor invokes the program instructions. When the program instructions are executed, they implement the steps of the intelligent diagnosis and treatment method for ovarian function recovery after transplantation based on DFO or its medicinal salts combined with VEGF-A or its medicinal salts as described in the fifth aspect of this invention.

[0050] The computer-readable storage medium stores a computer program that, when executed by a processor, implements the steps of the intelligent diagnostic and treatment method for post-ovarian transplantation functional recovery based on DFO or its medicated salts in combination with VEGF-A or its medicated salts, as described in the fifth aspect of the present invention.

[0051] When the computer program is executed by the processor, it implements the steps of the intelligent diagnostic and treatment method for post-ovarian transplantation function recovery based on DFO or its medicinal salts in combination with VEGF-A or its medicinal salts, as described in the fifth aspect of the present invention.

[0052] Advantages and beneficial effects of the present invention: This invention is the first to discover that DFO can effectively improve follicle survival rate, increase follicle number, and restore ovarian function and structure. Furthermore, this invention is the first to discover that the combination of DFO and VEGF-A has a synergistic effect on functional recovery after ovarian transplantation. This invention provides an effective drug and drug combination strategy for functional recovery after ovarian transplantation, and has broad application prospects in the field of ovarian repair drug development. Attached Figure Description

[0053] Figure 1 This is a schematic diagram of a smart diagnostic and treatment method for post-ovarian transplantation function recovery based on DFO or its pharmaceutically acceptable salts combined with VEGF-A or its pharmaceutically acceptable salts, provided as an embodiment of the present invention.

[0054] Figure 2 This is a schematic diagram of an intelligent diagnostic and treatment system for post-ovarian transplantation function recovery based on DFO or its medicinal salts combined with VEGF-A or its medicinal salts, provided as an embodiment of the present invention.

[0055] Figure 3 This is a schematic diagram of an intelligent diagnostic and treatment computer device for post-ovarian transplantation function recovery based on DFO or its pharmaceutically acceptable salts in combination with VEGF-A or its pharmaceutically acceptable salts, provided as an embodiment of the present invention.

[0056] Figure 4 The effects of DFO and DFO combined with VEGF-A on follicular morphology after ovarian transplantation. Detailed Implementation

[0057] The present invention will be further illustrated below with reference to specific embodiments. These embodiments are for illustrative purposes only and should not be construed as limiting the invention. Those skilled in the art will understand that various changes, modifications, substitutions, and variations can be made to these embodiments without departing from the principles and spirit of the invention. The scope of the invention is defined by the claims and their equivalents. The experimental consumables, reagents, and raw materials used in this invention are readily available to those skilled in the art and, unless otherwise specified, can be obtained commercially. Experimental methods not specifying specific conditions in this invention are generally performed under conventional conditions or according to the manufacturer's recommendations. In particular, the following embodiments are for illustrative purposes only and should not limit the scope of the invention in any way. It should be noted that the experimental conditions and results described in the following embodiments are for illustrative purposes only and should not, and will not, limit the invention as described in detail in the claims.

[0058] To enable those skilled in the art to better understand the present invention, the technical solutions of the present invention will be clearly and completely described below with reference to the accompanying drawings of the embodiments of the present invention. In some processes described in the specification, claims, and accompanying drawings of the present invention, multiple operations appearing in a specific order are included. However, it should be clearly understood that these operations may not be executed in the order they appear herein or may be executed in parallel. The operation numbers, such as S101, S102, S103, etc., are merely used to distinguish different operations and do not represent any execution order. Furthermore, these processes may include more or fewer operations, and these operations may be executed sequentially or in parallel.

[0059] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the protection scope of the present invention.

[0060] Figure 1 This is a schematic flowchart of an intelligent diagnostic and treatment method for post-ovarian transplantation function recovery based on DFO or its pharmaceutically acceptable salts combined with VEGF-A or its pharmaceutically acceptable salts, provided by an embodiment of the present invention. Specifically, the method includes: S101: Obtain relevant post-ovarian transplant functional information for the subject.

[0061] S102: Determine whether the subject is a patient whose ovarian function needs to be repaired after ovarian transplantation based on the relevant post-transplantation functional information data of the subject.

[0062] S103: When the subject is a patient whose ovarian function needs to be repaired after ovarian transplantation, the following treatment regimen shall be selected: administer a therapeutically effective amount of DFO or its pharmaceutically acceptable salt in combination with VEGF-A or its pharmaceutically acceptable salt to the subject.

[0063] In some embodiments, the post-ovarian transplantation functional information includes surgical history, symptoms and / or examination data: laboratory test data and / or pathological examination data.

[0064] In some embodiments, if laboratory test data shows that the subject's number of follicles, primordial follicle ratio, and / or antral follicle ratio are below the normal range, the atretic follicle ratio is above the normal range, and / or pathological examination data shows ovarian tissue structure damage, then the subject will be matched as a patient requiring ovarian transplantation for functional repair.

[0065] If the laboratory test data shows that the subject's follicle count, primordial follicle ratio, antral follicle ratio, and / or atretic follicle ratio are within the normal range and / or the pathological examination data shows that the ovarian tissue structure is intact, then the subject will be matched as a non-ovarian transplant recipient with functional repair needs.

[0066] In some embodiments, the information on post-ovarian transplantation functional elements is not limited to the surgical history, symptoms, and / or examination data described above. Any information known to those skilled in the art that can be used to clarify post-ovarian transplantation functional elements is included in the information on post-ovarian transplantation functional elements described in this invention. Furthermore, those skilled in the art can determine whether a subject is a patient whose ovarian function needs repair based on the above-mentioned information on post-ovarian transplantation functional elements and diagnostic criteria known in the art.

[0067] It should be noted that the innovation of this invention does not lie in the method for judging ovarian function after transplantation, but in the treatment plan adopted for patients whose ovarian function needs to be repaired after transplantation: administering a therapeutically effective amount of DFO or its pharmaceutically acceptable salt in combination with VEGF-A or its pharmaceutically acceptable salt to the subject (i.e., patients whose ovarian function needs to be repaired after transplantation).

[0068] In one specific embodiment, this invention demonstrates that DFO and DFO combined with VEGF-A can significantly improve the follicle survival rate and restore ovarian function in mice after ovarian transplantation, and that DFO combined with VEGF-A has a synergistic effect. This suggests the feasibility of an intelligent diagnostic and treatment method for ovarian transplantation function recovery based on DFO or its pharmaceutically acceptable salts combined with VEGF-A or its pharmaceutically acceptable salts. Specifically, as follows: I. Experimental Methods 1. Experimental materials: (1) Experimental animals: C57 mice, female, 12-16 weeks old, 8 mice per group.

[0069] (2) Drugs: DFO, MCE Corporation, 434644; VEGF-A, MCE Corporation, HY-J19145; Pregnant mare serum gonadotropin (PMSG), Solarbio, 2503190001; Human chorionic gonadotropin (hCG), Shanghai McLean, C17119846.

[0070] (3) Experimental grouping: ① Normal group: physiological saline; ②OTT (ovarian tissue transplantation) group: ovarian tissue transplantation; ③DFO+OTT group: After ovarian transplantation, DFO 100 mg / kg / d was administered intraperitoneally for 21 consecutive days; ④VEGF-A+OTT group: After ovarian transplantation, VEGF-A 8 μg / kg / d was administered via intraperitoneal injection for 1-5 days post-operation; ⑤DFO+VEGF-A+OTT group: After ovarian transplantation, DFO 100 mg / kg / d was administered intraperitoneally for 21 consecutive days; combined with VEGF-A 8 μg / kg / d, administered intraperitoneally for 1-5 days post-transplantation.

[0071] 2. Experimental Procedure (1) OTT model: Each mouse was anesthetized by intraperitoneal injection of 0.1 ml of 1.5% sodium pentobarbital. The skin on the back was prepared, and a small incision was made 2 cm above the groin. Fat was grasped with forceps, ovarian tissue was removed, the connection between the ovary and fallopian tube was cut, and the ovary was removed from the fat with fine forceps and temporarily placed in a culture dish containing physiological saline. The kidney was exposed through the same incision, a small incision was made in the renal capsule with a sterile blade, the capsule was gently lifted with fine forceps, the ipsilateral ovary was inserted, the kidney was repositioned, and the incision was sutured. After transplantation, 0.2 ml of physiological saline was injected daily. After 21 days, ovulation induction was initiated, and ovarian tissue was collected for subsequent testing.

[0072] (2) Detection of follicle number: 21 days after ovarian transplantation, mice were injected intraperitoneally with 10 IU of PMSG (100 IU / ml, 100 μl / mouse), and 48 hours later, an equivalent dose of hCG (100 IU / ml, 100 μl / mouse) was administered to promote ovulation. Ovaries were harvested 16 hours after hCG administration, fixed with 4% paraformaldehyde, and stained with hematoxylin and eosin (HE).

[0073] II. Experimental Results (1) Effects of DFO and DFO combined with VEGF-A on the number of follicles after ovarian transplantation Compared with the Con group, the OTT group had a reduced number of follicles and a lower survival rate; the DFO+OTT group significantly increased the number of follicles after ovarian transplantation, and the DFO+VEGF-A+OTT group had a synergistic effect on increasing the number of follicles (Table 1).

[0074] Table 1 Number of follicles (n=7)

[0075] # P<0.05 vs OTT (2) Effects of DFO and DFO combined with VEGF-A on the ratio of follicles at different stages after ovarian transplantation Compared with the Con group, the OTT group showed a decrease in the ratio of primordial follicles and antral follicles, and an increase in atretic follicles; both the DFO+OTT group and the VEGF-A+OTT group could significantly reverse this change, and the DFO+VEGF-A+OTT group had a synergistic effect (Table 2).

[0076] Table 2. Percentage of follicles at each stage of follicle development (%)

[0077] # P<0.05 vs OTT (3) Effects of DFO and DFO combined with VEGF-A on follicular morphology after ovarian transplantation In the Con group, the ovarian tissue of mice showed an intact overall structure with abundant and compactly arranged ovarian granulosa cells. Compared with the control group, the OTT group showed a disrupted overall ovarian tissue structure, scattered and disordered cells, loose and disordered arrangement of ovarian granulosa cells, and an increase in atretic follicles. Compared with the OTT group, the DFO+OTT group and the DFO+VEGF-A+OTT group showed improved overall ovarian tissue structure and a reduction in atretic follicles. The DFO+VEGF-A+OTT group also exhibited a synergistic effect. Figure 4 ).

[0078] Figure 2 This is a schematic diagram of an intelligent diagnostic and treatment system for post-ovarian transplantation function recovery based on DFO or its pharmaceutically acceptable salts combined with VEGF-A or its pharmaceutically acceptable salts, provided by an embodiment of the present invention. Specifically, the system includes: A diagnostic element information collector is used to collect functional element information after ovarian transplantation as described in the fifth aspect of the present invention and send the collected data results to a disease diagnosis matcher.

[0079] The disease diagnosis matcher is used to match the functional element information of the diagnostic element information collector with the disease type, and send the matched data results to the treatment plan matcher.

[0080] The treatment plan matcher is used to determine the matching result of the disease diagnosis matcher and call up the treatment plan according to the result, and then send the treatment plan data result to the disease diagnosis and treatment information output device.

[0081] The disease diagnosis and treatment information output device is used to output the data results received from the disease diagnosis matcher and treatment plan matcher to the receiving unit.

[0082] In the treatment plan matcher, if the disease diagnosis matcher matches the subject as a patient whose ovarian function needs to be repaired after ovarian transplantation, the following treatment plan is matched and invoked: administering a therapeutically effective amount of DFO or its pharmaceutically acceptable salt in combination with VEGF-A or its pharmaceutically acceptable salt to the subject.

[0083] In the treatment matching device, if the disease diagnosis matching device matches the subject as a non-ovarian transplant patient requiring functional repair, then there is no need to match and invoke the following treatment plan: administering a therapeutically effective amount of DFO or its pharmaceutically acceptable salt in combination with VEGF-A or its pharmaceutically acceptable salt to the subject.

[0084] In some embodiments, the receiving unit is a display screen, a computer client, a mobile client, or a tablet.

[0085] Figure 3 This is a schematic diagram of a computer device for intelligent diagnosis and treatment of ovarian function recovery after transplantation based on DFO or its medicinal salts combined with VEGF-A or its medicinal salts, provided by an embodiment of the present invention. The device includes a memory and a processor. The memory is used to store program instructions; the processor is used to call the program instructions. When the program instructions are executed, they implement the steps of the intelligent diagnosis and treatment method for ovarian function recovery after transplantation based on DFO or its medicinal salts combined with VEGF-A or its medicinal salts as described in the fifth aspect of the present invention.

[0086] In some embodiments, the intelligent diagnostic and treatment computer device for post-ovarian transplant functional recovery based on DFO or its pharmaceutically acceptable salts in combination with VEGF-A or its pharmaceutically acceptable salts may further include an input device and an output device.

[0087] In some embodiments, the memory, processor, input device, and output device may be connected via a bus or other means. Figure 3 The above description uses a bus connection as an example; the memory is used to store program instructions; the processor is used to call program instructions, and when the program instructions are executed, they are used to implement the above method.

[0088] In some embodiments, memory can be understood as any device for storing programs, and processor can be understood as a device for using programs.

[0089] In the several embodiments provided in this application, it should be understood that the disclosed systems, apparatuses, and methods can be implemented in other ways. For example, the apparatus embodiments described above are merely illustrative; for instance, the division of units is only a logical functional division, and in actual implementation, there may be other division methods. For example, multiple units or components may be combined or integrated into another system, or some features may be ignored or not executed. Furthermore, the coupling or direct coupling or communication connection shown or discussed may be indirect coupling or communication connection through some interfaces, apparatuses, or units, and may be electrical, mechanical, or other forms.

[0090] The units described as separate components may or may not be physically separate. The components shown as units may or may not be physical units; that is, they may be located in one place or distributed across multiple network units. Some or all of the units can be selected to achieve the purpose of this embodiment according to actual needs.

[0091] Furthermore, the functional units in the various embodiments of the present invention can be integrated into one processing unit, or each unit can exist physically separately, or two or more units can be integrated into one unit. The integrated unit can be implemented in hardware or as a software functional unit.

[0092] Those skilled in the art will understand that all or part of the steps in the various methods of the above embodiments can be implemented by a program instructing related hardware. The program can be stored in a computer-readable storage medium, which may include: read-only memory (ROM), random access memory (RAM), disk or optical disk, etc.

[0093] The computer device provided by the present invention has been described in detail above. For those skilled in the art, there will be changes in the specific implementation and application scope based on the ideas of the embodiments of the present invention. Therefore, the content of this specification should not be construed as a limitation of the present invention.

[0094] The above description of the embodiments is only for understanding the method and core ideas of the present invention. It should be noted that those skilled in the art can make various improvements and modifications to the present invention without departing from the principles of the invention, and these improvements and modifications will also fall within the protection scope of the claims of the present invention.

Claims

1. A drug for promoting functional recovery after ovarian transplantation, characterized in that, The drug is DFO or its pharmaceutically acceptable salt.

2. The drug according to claim 1, characterized in that, The DFO or its pharmaceutically usable salt contains 100 mg per kilogram.

3. A pharmaceutical composition for promoting functional recovery after ovarian transplantation, characterized in that, The active ingredient of the pharmaceutical composition is composed of DFO or its pharmaceutically acceptable salt in combination with VEGF-A or its pharmaceutically acceptable salt; Preferably, the mass ratio of DFO or its pharmaceutically acceptable salt to VEGF-A or its pharmaceutically acceptable salt is 100:0.008; Preferably, the DFO or its pharmaceutically acceptable salt per kilogram contains 100 mg. Preferably, the individual mass of VEGF-A or its pharmaceutically usable salt is 8 μg per kilogram.

4. The use of the DFO of claim 1 or its pharmaceutically acceptable salt, or the DFO of claim 3 or its pharmaceutically acceptable salt combined with VEGF-A or its pharmaceutically acceptable salt, in the preparation of a medicament for promoting ovarian function recovery after transplantation.

5. A pharmaceutical preparation for promoting functional recovery after ovarian transplantation, characterized in that, The pharmaceutical preparation comprises the drug of claim 1 or the pharmaceutical composition of claim 3; Preferably, the pharmaceutical preparation further includes pharmaceutically acceptable excipients; Preferably, the dosage form of the pharmaceutical preparation includes an oral dosage form, a parenteral dosage form, or a topical dosage form.

6. A smart diagnostic and treatment method for post-ovarian transplant functional recovery based on DFO or its pharmaceutically acceptable salts combined with VEGF-A or its pharmaceutically acceptable salts, characterized in that, The method includes the following steps: S101: Obtain relevant post-ovarian transplant functional information of the subject; S102: Determine whether the subject is a patient whose ovarian function needs to be repaired after ovarian transplantation based on the subject's relevant post-transplantation functional element information data; S103: When the subject is a patient whose ovarian function needs to be repaired after ovarian transplantation, the following treatment regimen shall be selected: administer a therapeutically effective amount of DFO or its pharmaceutically acceptable salt in combination with VEGF-A or its pharmaceutically acceptable salt to the subject.

7. The intelligent diagnostic and treatment method for post-ovarian transplant functional recovery based on DFO or its pharmaceutically acceptable salts combined with VEGF-A or its pharmaceutically acceptable salts, as described in claim 6, is characterized in that... The functional information after ovarian transplantation includes surgical history, symptoms and / or examination data: laboratory test data and / or pathological examination data; If the laboratory test data shows that the subject's number of follicles, primordial follicle ratio and / or antral follicle ratio are below the normal range, the atretic follicle ratio is above the normal range, and / or the pathological examination data shows that the ovarian tissue structure is damaged, then the subject will be matched as a patient whose ovarian function needs to be repaired after ovarian transplantation. If the laboratory test data shows that the subject's follicle count, primordial follicle ratio, antral follicle ratio, and / or atretic follicle ratio are within the normal range and / or the pathological examination data shows that the ovarian tissue structure is intact, then the subject will be matched as a non-ovarian transplant recipient with functional repair needs.

8. A smart diagnostic and treatment system for post-ovarian transplant functional recovery based on DFO or its pharmaceutically acceptable salts combined with VEGF-A or its pharmaceutically acceptable salts, characterized in that, The system includes: A diagnostic element information collector is used to collect functional element information after ovarian transplantation as described in claim 7 and send the collected data results to a disease diagnosis matcher. The disease diagnosis matcher is used to match the functional element information of the diagnostic element information collector with the disease type, and send the matched data results to the treatment plan matcher. The treatment plan matcher is used to determine the matching result of the disease diagnosis matcher and call the treatment plan according to the result, and then send the treatment plan data result to the disease diagnosis and treatment information output device. The disease diagnosis and treatment information output device is used to output the data results received from the disease diagnosis matcher and treatment plan matcher to the receiving unit; In the treatment plan matcher, if the disease diagnosis matcher matches the subject as a patient whose ovarian function needs to be repaired after ovarian transplantation, the following treatment plan is matched and invoked: administer a therapeutically effective amount of DFO or its pharmaceutically acceptable salt in combination with VEGF-A or its pharmaceutically acceptable salt to the subject; In the treatment matching device, if the disease diagnosis matching device matches the subject as a non-ovarian transplant patient requiring functional repair, then there is no need to match and invoke the following treatment plan: administering a therapeutically effective amount of DFO or its pharmaceutically acceptable salt in combination with VEGF-A or its pharmaceutically acceptable salt to the subject.

9. The intelligent diagnostic and treatment system for post-ovarian transplant functional recovery based on DFO or its pharmaceutically acceptable salts combined with VEGF-A or its pharmaceutically acceptable salts, as described in claim 8, is characterized in that... The receiving unit can be a display screen, a computer client, a mobile client, or a tablet.

10. A computer device, computationally readable storage medium, or computer program product for intelligent diagnosis and treatment of post-ovarian transplantation functional recovery based on DFO or its pharmaceutically acceptable salts in combination with VEGF-A or its pharmaceutically acceptable salts, comprising a computer program, characterized in that, The device includes a memory and a processor. The memory is used to store program instructions. The processor is used to call the program instructions, and when the program instructions are executed, to implement the steps of the intelligent diagnostic and treatment method for post-ovarian transplantation function recovery based on DFO or its medicated salts combined with VEGF-A or its medicated salts as described in claim 6. The computer-readable storage medium stores a computer program, which, when executed by a processor, implements the steps of the intelligent diagnostic and treatment method for post-ovarian transplantation function recovery based on DFO or its medicated salts in combination with VEGF-A or its medicated salts as described in claim 6. When the computer program is executed by the processor, it implements the steps of the intelligent diagnostic and treatment method for ovarian function recovery after transplantation based on DFO or its medicinal salts in combination with VEGF-A or its medicinal salts as described in claim 6.